# Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients

> **NCT02311647** · — · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 120 (estimated)

## Conditions studied

- Endometrial Receptivity Post Tamoxifen Exposure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02311647
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311647, "Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02311647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*